Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/06/2005US20050222166 N-Aminocarbonylpiperazine, e.g., 1-(p-fluorophenylaminoacrbonyl-)- or 1-(p-fluorophenylsulfonylaminocarbonyl)-4-(4-(bis(p-fluorophenyl)methoxybutyl))piperazine; treating neurodegenerated diseases
10/06/2005US20050222165 Specific alpha-adrenoceptor antagonists and muscarinic antagonists are administered simultaneously, separately or sequentially to treat the lower urinary tract symptoms associated with benign prostate hyperplasia
10/06/2005US20050222163 Combinations of signal transduction inhibitors
10/06/2005US20050222162 Administering, to a patient in need of such treatment, an effective amount of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof
10/06/2005US20050222161 Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
10/06/2005US20050222160 1-[3-(3-cyclopentyloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyridazin-1-yl]-1-[4-methyl-2-(1-oxypyridin-2-yl)thiazol-5-yl]methanone, used for inhibiting proliferation of lymphocytes in a host, and for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, arthritis, multiple sclerosis, diabetes
10/06/2005US20050222158 Method of treating migraine headaches using calcitonin gene related peptide mimetics
10/06/2005US20050222157 Methods of treatment of menopause and perimenopause using eszopiclone
10/06/2005US20050222156 Methods of treatment of chronic pain using eszopiclone
10/06/2005US20050222155 Inhibitors of akt activity
10/06/2005US20050222154 5-{[6-Fluoro-2,5-dihydroxy-4,4,7-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalen-1-yl]amino}-isoquinolin-1(2H)-one; anti-allergic, immunosuppressive and antiproliferative action
10/06/2005US20050222153 Tyrosine kinase enzyme inhibitors as growth factor receptors and useful as antiproliferation agents
10/06/2005US20050222152 Enzyme inhibitors for disease treatment with Cathepsin s
10/06/2005US20050222151 Non-Imidazole heterocyclic compounds
10/06/2005US20050222150 6-(p-morpholinoanilino)-4-(4-substituted-1-piperazinyl)-2-(methylthio)pyrimidines having an excellent inhibitory effect on replication of Hepatitis C virus
10/06/2005US20050222149 For therapy of neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal
10/06/2005US20050222148 Phenylaminopropanol derivatives and methods of their use
10/06/2005US20050222147 Process for the preparation of morpholine derivatives and intermediates therefore
10/06/2005US20050222146 N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
10/06/2005US20050222144 Medicaments for the treatment of chronic obstructive pulmonary disease
10/06/2005US20050222141 N-(2,6-dichlorobenzoyl)-4-[1-methyl-7-(pyrrolidine-1-ylmethyl)-2,4-quinazoline-dione-3-yl]-L-phenylalanine trifluoroacetate; 4 integrin antagonist; antiinflammatory, anticarcinogenic agent, antiallergent; asthma, psoriasis, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation
10/06/2005US20050222140 Improved DP-IV inhibitors increase the steady state concentrations of GLP-1 and GIP, resulting in improved glucose tolerance
10/06/2005US20050222139 Non-peptide gnrh antagonists
10/06/2005US20050222138 Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
10/06/2005US20050222137 Combination of organic compounds
10/06/2005US20050222136 Active substance combination
10/06/2005US20050222135 Active substance combination
10/06/2005US20050222134 Crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one
10/06/2005US20050222133 Process for preparing pyrrolo[2, 1-c] [1,4] benzodiazepine hybrids
10/06/2005US20050222132 for example, 7-methoxy-8-[n'-(4''-acridonylcarboxyamido)alkyl]-oxy-(11aS)-1,2,3,11a-tetraydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one; antitumor agents
10/06/2005US20050222131 Useful as antitumour agents
10/06/2005US20050222130 Inhibitors of RhoA kinase production/activation for relaxing the features of and/or for decontracting the skin
10/06/2005US20050222129 Non-imidazole heterocyclic compounds
10/06/2005US20050222128 Compounds for the treatment of diseases
10/06/2005US20050222127 Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
10/06/2005US20050222126 Antiangiogenic compounds and an assay for inhibitors of cell invasion
10/06/2005US20050222125 For therapy of depression, anxiety and body weight disorders
10/06/2005US20050222124 Benzenesulfonamide derivatives as antipsychotic agents
10/06/2005US20050222123 Cholinesterase inhibitors for treating inflammation
10/06/2005US20050222122 Statin therapy for enhancing cognitive maintenance
10/06/2005US20050222121 Atypical antipsychotic agents having low affinity for the D2 receptor
10/06/2005US20050222119 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
10/06/2005US20050222118 For therapy of inflammatory or allergic condition
10/06/2005US20050222117 Chlorophyll and its derivatives for cancer photodynamic therapy
10/06/2005US20050222116 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue
10/06/2005US20050222115 Bile acid derived steroidal dimers with novel amphiphilic topology having antifungal activity
10/06/2005US20050222114 Use of new etonogestrel esters
10/06/2005US20050222113 New etonogestrel esters
10/06/2005US20050222112 Treating psychological dependency (not physical dependancy leading towithdrawal) by administering the agonist (cortisone acetate) and the addictive drug after detoxification of the dependent-patient; highly-dosed and "imprinted"by the mixture eliminates and replaces the "addiction memory"
10/06/2005US20050222111 Method for treating a respiratory disease
10/06/2005US20050222110 Use of loteprednol etabonate for the treatment of dry eye
10/06/2005US20050222109 Crystalline 19-norsteroids
10/06/2005US20050222106 Drospirenone-containing preparations for transdermal use
10/06/2005US20050222105 Nitric ester derivatives of hormones such as progesterone, used for preventing premature labor, increasing cervical dilatation, in hormone replacement therapy, as hypeortensive agents and for treating dysmenorrhea
10/06/2005US20050222104 e.g. 3 beta -Formyloxy-21-acetyloxy-5-pregnen-20-one; modulate immunology response; disease associated to an excess of glucocorticoids; Cushing's syndrome, iatrogenic hypercortisolism or depression
10/06/2005US20050222103 Airway alkalinization as therapy for airway diseases
10/06/2005US20050222102 Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroids
10/06/2005US20050222101 Method and composition for treatment of skin conditions
10/06/2005US20050222100 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
10/06/2005US20050222099 Pregnane steroids for use in the treatment of cns disorders
10/06/2005US20050222098 Regulation of meiosis
10/06/2005US20050222097 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity
10/06/2005US20050222096 Drug screening for modulators having aspirin activity but not thrombin activatable fibrinolysis inhibitory activity; ortho-hydroxybenzamides; anticoagulants
10/06/2005US20050222095 Anti-bacterial plant compositions
10/06/2005US20050222094 Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester
10/06/2005US20050222093 Methods for restoring cognitive function following systemic stress
10/06/2005US20050222092 Use of s1p receptor agonists in heart diseases
10/06/2005US20050222091 Use of tyrosine kinase inhibitors for treating cns disorders
10/06/2005US20050222090 2-Amino,6-cyclopropyl,9-((bis(alkoxycarbonylalkylamino-)phosphinyl)-methoxyethyl-)purine;viricides; papilloma virus; urogental disorders; antiapoptosis; prodrugs; oral drug delivery; bioavailability
10/06/2005US20050222089 taxane is prepared by esterifying an appropriate baccatin carrying a C-13 hydroxyl functional group with an acid derivative and is obtained by controlled saponification
10/06/2005US20050222087 Hedgehog antagonists that inhibit the hedgehog pathway in a smoothened gain-of-function cell with an IC50 within a factor of 20, 10, or even a factor of 5, of the IC50 with which they inhibit the hedgehog pathway in a patched-null cell
10/06/2005US20050222085 Quaternised ammonium cyclodextrin compounds
10/06/2005US20050222084 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
10/06/2005US20050222083 Thiol-modified hyaluronan
10/06/2005US20050222081 Cross-linked hyaluronate compounds
10/06/2005US20050222080 Cycloglycans suitable to inhibit mammalian infection
10/06/2005US20050222079 Preparation containing folic acid, vitamin b6, and vitamin b12, and use thereof
10/06/2005US20050222078 Use of pyrimidine nucleotides for the treatment of affections of the peripheral nervous system
10/06/2005US20050222077 Administering to a subject before the onset of an ischemic episode at daily dosages of 1-2 g of free CDP-choline (CITICOLINE)
10/06/2005US20050222076 Composition for cell proliferation
10/06/2005US20050222074 Modulators of bone homeostasis identified in a high-throughput screen
10/06/2005US20050222071 Topical administration of at least one double-stranded RNA oligonucleotide (dsRNA)
10/06/2005US20050222068 Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
10/06/2005US20050222065 Vascular therapeutics
10/06/2005US20050222064 Polycationic compositions for cellular delivery of polynucleotides
10/06/2005US20050222061 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
10/06/2005US20050222060 Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
10/06/2005US20050222056 Heterocyclic compounds and their use in the detection of nucleic acids
10/06/2005US20050222054 Combination comprising a CDK inhibitor and doxorubicin
10/06/2005US20050222053 Iridoid-saccharide compound and method of using same
10/06/2005US20050222050 Compositions and methods for reducing or preventing obesity
10/06/2005US20050222049 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
10/06/2005US20050222048 Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
10/06/2005US20050222047 Compounds as enzyme inhibitors to treat hepatitis with viricides
10/06/2005US20050222046 Pharmaceutical preparations of glutathione and methods of administration thereof
10/06/2005US20050222043 Use of proteasome inhibitor in the treatment of fibrotic diseases
10/06/2005US20050222019 Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant
10/06/2005US20050222016 Nucleoside analogs in combination therapy of herpes simplex infections
10/06/2005US20050222014 Administering phosphodiestarase inhibitors and melanocortin receptor antagonist: synergistic mixture
10/06/2005US20050222013 Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
1 ... 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 ... 7860